This pharmacological agent, initially developed for the management of type 2 diabetes mellitus , has shown promising results in weight loss, sparking interest and debate in medicine
Tirzepatide, a cutting-edge weight loss injection, is a dual GLP-1/GIP receptor agonist approved by the FDA
At Genesis Lifestyle Medicine, were here to support your health journey wherever life takes you
"Fatty liver disease is estimated to affect up to one in five people in Sweden, many of whom have type 2 diabetes, and about one in twenty develop severe liver disease," study first author Axel Wester, assistant professor at the Department of Medicine, Huddinge, Karolinska Institutet, said in a press release
they tend to fade over time, but for some people, they can be a persistent nuisance